Novel tPA-neutralising antidote

The availability of an antidote to address possible intracranial bleeding caused by tPA, the current gold standard treatment for Ischemic Stroke, has the potential to save lives and reduce disability in multiple patients worldwide.

The Problem

tPA is a life-saving drug, but can cause severe bleeding, often into the brain, which is difficult to control. As a result it has limited usage.

The Solution

EmstoPA is an emergency treatment, stopping the bleeding and saving lives as well as reducing disability

Unmet Need

There is a recognised need to be able to rapidly reverse the effects of tPA and EmstoPA is the first such product.